"The annual investment
on research
amount to
10% of turnover."

Upsher-Smith And Rafarm announce launch of Moxifloxacin Ophthalmic Solution, USP 0.5%. First product to enter the U.S. market under partnership agreement which includes development and distribution of six ophthalmic and otic ANDA products.

read the press release

MOXIFLOXACIN OTHALMIC SOLUTION UPSHER-SMITH

 

footerlogo Copyright Rafarm © 2014
All rights reserved
Privacy Policy